Developer docs
API playgroundTry for free, no card

Search company profiles

CarThera

Full company profile

uuid0000r16

Namestring
CarThera
Legal namestring
Carthera S.A.
Websiteurl
carthera.eu
Company typeenum
Private
Founded yearint
2010
Descriptiontext

CarThera is a clinical-stage medical device company developing the SonoCloud®, an implantable ultrasound-based system designed to temporarily and repeatedly open the blood-brain barrier (BBB) in order to enhance the delivery of therapeutic agents to the brain. Founded in 2010 and headquartered in Lyon, France (legally registered in Paris), with a US subsidiary in New York, the company targets recurrent glioblastoma as its primary indication, with additional programs in brain metastases, Alzheimer's disease, ALS, pediatric brain tumors, and tauopathies. The platform exists in two variants — SonoCloud-1 (single emitter) and SonoCloud-9 (nine emitters, used in the pivotal SONOBIRD trial) — and operates via low-intensity pulsed ultrasound triggered before intravenous chemotherapy infusion to transiently disrupt the BBB.

The company's business model is currently pre-revenue: SonoCloud® is supplied exclusively for investigational use across clinical trial sites and is not approved for commercial sale in any geography. Revenue mechanics will depend on a combination of direct device sales (or capital placement) to neuro-oncology centers, per-procedure consumable economics, and partnership-driven combination therapies with pharmaceutical partners, but none of these revenue streams are yet realized. CarThera has raised approximately €42M cumulatively (most recently a €37.5M Series B in June 2023 extended by €4.5M in December 2023), operates with 29 full-time specialists, runs 5 ongoing clinical trials with 3 international pharma partners, and holds FDA Breakthrough Device Designation and EMA Orphan Medical Device Status alongside ISO 13485:2016 certification.

Short descriptiontext

CarThera is a clinical-stage medical device company developing SonoCloud®, an implantable ultrasound system that temporarily opens the blood-brain barrier to enhance therapeutic drug delivery, primarily for recurrent glioblastoma and other neurological oncology indications.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersLyon, France
HQ citystring
Lyon
HQ countrystring
France
HQ regionstring
Europe
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
therapeutic ultrasound devices, blood-brain barrier opening, brain drug delivery, neuro-oncology medical devices, intracranial ultrasound implants
NAICS code1 code
  • Electromedical and Electrotherapeutic Apparatus Manufacturing334510
SIC code1 code
  • Surgical & Medical Instruments & Apparatus3841
Product category
Therapeutic Ultrasound Medical Devices
Social media profiles2 records
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Medical Device Sales
TypeOne Time License
Description

Pre-revenue clinical-stage company. Products are in clinical or preclinical evaluation and not approved for marketing by regulatory authorities (not EMA or FDA approved). Products are not for sale and are for investigational use only. Revenue will be generated upon successful regulatory approval and commercialization of SonoCloud® devices.

carthera.eu
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Operations, Others, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 6 records shown
1SonoCloud
Description

SonoCloud is an intracranial implant device that emits low-intensity pulsed ultrasound to temporarily open the blood-brain barrier, enabling enhanced drug delivery for brain disorders. Versions include SonoCloud-1 and SonoCloud-9.

carthera.eu
+5 more records
Core offering1 text field

CarThera develops the SonoCloud® platform, an implantable ultrasound-based medical device system that emits low-intensity pulsed ultrasound (LIPU) to temporarily and reversibly open the blood-brain barrier (BBB). The system consists of an intracranial implant (SonoCloud-1 or SonoCloud-9), an external generator, and a transdermal needle for activation. Four minutes of ultrasound opens the BBB for several hours, enabling 4-6x increased concentration of therapeutic molecules in the brain for treatment of glioblastoma, brain metastases, and neurodegenerative diseases.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • 4-6x increase in drug concentrations in brain tissue after SonoCloud-9 mediated BBB opening
+3 more records
Product overview1 text field

CarThera is a clinical-stage medtech company developing the SonoCloud® platform - an ultrasound-based medical device system designed to temporarily open the blood-brain barrier (BBB). The core product family includes SonoCloud-1 (single-emitter) and SonoCloud-9 (nine-emitter) implantable devices, used in combination with an external generator and transdermal needle. The system delivers low-intensity pulsed ultrasound (LIPU) to create reversible BBB disruption for 4-6 hours, enabling enhanced delivery of chemotherapy and immunotherapy agents. The platform is being developed for glioblastoma, brain metastases, and neurodegenerative diseases including Alzheimer's. The SonoCloud-9 is the most clinically advanced version in pivotal Phase 3 trials (SONOBIRD study), while earlier versions and components support the complete therapeutic workflow.

Product and service3 records
1SonoCloud-9 Implant
CategoryTherapeutic ultrasound implant (core product)
Description

Nine-emitter implantable ultrasound device that temporarily opens the blood-brain barrier using low-intensity pulsed ultrasound (LIPU), enabling 4-6x increased concentration of therapeutic molecules in the brain. The device is implanted in a skull window, below the skin, and activated for a few minutes using a transdermal needle connected to an external control unit. It is MRI-compatible and designed for repeated use during chemotherapy cycles in patients with glioblastoma, brain metastases, and other severe brain disorders.

2SonoCloud-1 Implant
CategoryTherapeutic ultrasound implant (core product)
Description

First-generation single-emitter intracranial ultrasound implant for temporarily disrupting the blood-brain barrier to facilitate therapeutic agent delivery to the brain. Validated in early Phase I/IIa clinical trials and serves as the precursor to the multi-emitter SonoCloud-9 system.

3SonoCloud-9 System
CategoryTherapeutic ultrasound medical device system (core product)
Description

Complete ultrasound-based medical device system for temporarily opening the blood-brain barrier, comprising the SonoCloud-9 implantable device, the transdermal needle, and the external generator. MRI-compatible and designed for repeated use during chemotherapy cycles to enable enhanced drug delivery to the brain.

Scale indicator6 records

Each record includes

Type, Value, Description, Source

Partnership8 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-04-09
Description

Partnership with Agenus and Northwestern University for Phase 2a trial combining SonoCloud-9® with checkpoint inhibitors (anti-CTLA-4, anti-PD-1) to treat newly diagnosed glioblastoma. World-first trial that could change standard of care for unmethylated glioblastoma patients.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2023-11-06
Description

Strategic collaboration with Accord Healthcare Limited, a leading pharmaceutical company, for the supply of carboplatin. This partnership ensures reliable drug supply for clinical trials and potential commercialization of the SonoCloud®-carboplatin combination therapy.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2019-12-09
Description

Strategic collaboration with US-based Lantheus to provide microbubbles for use with the SonoCloud device. Microbubbles are an essential component of the LIPU technology as they oscillate when exposed to ultrasound to trigger BBB opening.

Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2019-11-18
Description

Clinical collaboration with KIYATEC to advance innovation and improve treatments for patients with glioblastoma, potentially incorporating personalized medicine approaches.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Long-standing research and clinical collaboration with Northwestern University in Chicago for development of SonoCloud technology. Multiple joint clinical trials including SC9-ABX (Phase 1/2 with nab-paclitaxel) and SC9-IMMUNO (Phase 2a with checkpoint inhibitors). Dr. Amy Heimberger and Dr. Adam Sonabend from Northwestern are key collaborators.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Spin-off from AP-HP, the largest hospital group in Europe. Ongoing institutional collaboration for multiple clinical trials including SONOFIRST, SONOKID, and BOREAL. Professor Alexandre Carpentier, founder and inventor, is chief of neurosurgery at Pitié-Salpêtrière University Hospital (AP-HP).

Strategic tierMinorTypeStrategic or Co-development Partner
Description

Research collaboration with INSERM (French National Institute of Health and Medical Research) for pre-clinical and translational research on therapeutic ultrasound.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

Collaboration with University of California San Francisco for clinical research and development of SonoCloud technology. Dr. Mitchel Berger, Director of the Brain Tumor Center at UCSF, serves on Carthera's Scientific Advisory Board.

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

InSightec develops transcranial MR-guided focused ultrasound systems for non-invasive blood-brain barrier opening and other neurological applications. It is a direct peer in the ultrasound-mediated BBB opening category, though its approach is non-invasive rather than implantable.

TypeEmerging player
Description

NaviFUS is a Taiwan-based clinical-stage company developing non-invasive focused ultrasound for blood-brain barrier opening in glioblastoma and other CNS indications. It is an emerging peer pursuing a similar therapeutic mechanism through a different delivery modality.

TypeDirect peer
Description

NovoCure markets Tumor Treating Fields (TTFields) therapy for newly diagnosed and recurrent glioblastoma. It is a direct commercial peer serving the same primary indication with a novel device-based mechanism, representing the standard-of-care alternative SonoCloud would need to displace or complement.

4EDAP TMS
TypeBroad incumbent
Description

EDAP TMS is a publicly listed therapeutic ultrasound company commercializing high-intensity focused ultrasound (HIFU) for prostate cancer and other urological indications. It is a broad incumbent in therapeutic ultrasound, and CarThera's CEO previously led the launch of EDAP's Ablatherm device.

TypeBroad incumbent
Description

Profound Medical develops MR-guided transurethral ultrasound ablation systems primarily for prostate disease. It is a broad incumbent in the therapeutic ultrasound category using overlapping core technology (focused ultrasound ablation) for adjacent clinical applications.

TypeEmerging player
Description

Theraclion is a French clinical-stage company developing high-intensity focused ultrasound (HIFU) for benign thyroid and breast tumors. It is an emerging peer in the European therapeutic ultrasound space with comparable modality but non-overlapping indications.

TypeBroad incumbent
Description

Sonablate (SonaCare Medical) commercializes high-intensity focused ultrasound ablation systems for prostate tissue. It is a broad incumbent in the HIFU device category, with overlapping ultrasound ablation technology but a different clinical focus.

TypeEmerging player
Description

Cordance Medical is an emerging company developing non-invasive focused ultrasound for transient BBB opening to enable drug delivery. It targets the same core mechanism as SonoCloud without the implant, making it a thematic emerging peer in the BBB-opening space.

9Diffusion Pharmaceuticals (Aadi Bioscience)
TypeDirect peer
Description

Aadi Bioscience focuses on treating rare cancers including glioblastoma with nanoparticle albumin-bound therapeutics. It is a direct peer serving the same recurrent glioblastoma indication with a complementary drug-delivery approach seeking to overcome the BBB.

TypeEmerging player
Description

Medicenna Therapeutics develops IL-2 and IL-4 Superkines for recurrent glioblastoma and other solid tumors. It is an emerging peer competing in the same recurrent GBM indication with a novel immunotherapeutic approach, often cited as a comparable clinical-stage oncology biotech.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers3 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles6 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries1 record

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance1 record

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds8 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors10 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

CarThera

Therapeutic Ultrasound Medical Devicescarthera.eu

CarThera is a clinical-stage medical device company developing SonoCloud®, an implantable ultrasound system that temporarily opens the blood-brain barrier to enhance therapeutic drug delivery, primarily for recurrent glioblastoma and other neurological oncology indications.

What CarThera does

CarThera is a clinical-stage medical device company developing the SonoCloud®, an implantable ultrasound-based system designed to temporarily and repeatedly open the blood-brain barrier (BBB) in order to enhance the delivery of therapeutic agents to the brain. Founded in 2010 and headquartered in Lyon, France (legally registered in Paris), with a US subsidiary in New York, the company targets recurrent glioblastoma as its primary indication, with additional programs in brain metastases, Alzheimer's disease, ALS, pediatric brain tumors, and tauopathies. The platform exists in two variants — SonoCloud-1 (single emitter) and SonoCloud-9 (nine emitters, used in the pivotal SONOBIRD trial) — and operates via low-intensity pulsed ultrasound triggered before intravenous chemotherapy infusion to transiently disrupt the BBB.

The company's business model is currently pre-revenue: SonoCloud® is supplied exclusively for investigational use across clinical trial sites and is not approved for commercial sale in any geography. Revenue mechanics will depend on a combination of direct device sales (or capital placement) to neuro-oncology centers, per-procedure consumable economics, and partnership-driven combination therapies with pharmaceutical partners, but none of these revenue streams are yet realized. CarThera has raised approximately €42M cumulatively (most recently a €37.5M Series B in June 2023 extended by €4.5M in December 2023), operates with 29 full-time specialists, runs 5 ongoing clinical trials with 3 international pharma partners, and holds FDA Breakthrough Device Designation and EMA Orphan Medical Device Status alongside ISO 13485:2016 certification.

CarThera firmographics

Firmographics
Name
CarThera
Legal name
Carthera S.A.
Website
https://carthera.eu
Company type
Private
Founded year
2010
Operating status
Operating
Headcount range
11–50 employees
Short description
CarThera is a clinical-stage medical device company developing SonoCloud®, an implantable ultrasound system that temporarily opens the blood-brain barrier to enhance therapeutic drug delivery, primarily for recurrent glioblastoma and other neurological oncology indications.
Ownership category
akta.pro rank

Where CarThera is headquartered

Location

Headquarters

HQ city
Lyon
HQ country
France
HQ region
Europe

Offices2 records

Markets served

CarThera business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Others, Marketing or Sales

Revenue model

  1. Medical Device Sales: Pre-revenue clinical-stage company. Products are in clinical or preclinical evaluation and not approved for marketing by regulatory authorities (not EMA or FDA approved). Products are not for sale and are for investigational use only. Revenue will be generated upon successful regulatory approval and commercialization of SonoCloud® devices.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels6 records

CarThera product offering

Product offering

Core offering

CarThera develops the SonoCloud® platform, an implantable ultrasound-based medical device system that emits low-intensity pulsed ultrasound (LIPU) to temporarily and reversibly open the blood-brain barrier (BBB). The system consists of an intracranial implant (SonoCloud-1 or SonoCloud-9), an external generator, and a transdermal needle for activation. Four minutes of ultrasound opens the BBB for several hours, enabling 4-6x increased concentration of therapeutic molecules in the brain for treatment of glioblastoma, brain metastases, and neurodegenerative diseases.

Product overview

CarThera is a clinical-stage medtech company developing the SonoCloud® platform - an ultrasound-based medical device system designed to temporarily open the blood-brain barrier (BBB). The core product family includes SonoCloud-1 (single-emitter) and SonoCloud-9 (nine-emitter) implantable devices, used in combination with an external generator and transdermal needle. The system delivers low-intensity pulsed ultrasound (LIPU) to create reversible BBB disruption for 4-6 hours, enabling enhanced delivery of chemotherapy and immunotherapy agents. The platform is being developed for glioblastoma, brain metastases, and neurodegenerative diseases including Alzheimer's. The SonoCloud-9 is the most clinically advanced version in pivotal Phase 3 trials (SONOBIRD study), while earlier versions and components support the complete therapeutic workflow.

Differentiator

Problem solved

Functional benefit

Brands

  • SonoCloud: SonoCloud is an intracranial implant device that emits low-intensity pulsed ultrasound to temporarily open the blood-brain barrier, enabling enhanced drug delivery for brain disorders. Versions include SonoCloud-1 and SonoCloud-9.
  • SONOBIRD
  • SONOFIRST
  • SONOKID
  • SONIMEL
  • BOREAL

Products and services

  • SonoCloud-9 Implant Nine-emitter implantable ultrasound device that temporarily opens the blood-brain barrier using low-intensity pulsed ultrasound (LIPU), enabling 4-6x increased concentration of therapeutic molecules in the brain. The device is implanted in a skull window, below the skin, and activated for a few minutes using a transdermal needle connected to an external control unit. It is MRI-compatible and designed for repeated use during chemotherapy cycles in patients with glioblastoma, brain metastases, and other severe brain disorders.
  • SonoCloud-1 Implant First-generation single-emitter intracranial ultrasound implant for temporarily disrupting the blood-brain barrier to facilitate therapeutic agent delivery to the brain. Validated in early Phase I/IIa clinical trials and serves as the precursor to the multi-emitter SonoCloud-9 system.
  • SonoCloud-9 System Complete ultrasound-based medical device system for temporarily opening the blood-brain barrier, comprising the SonoCloud-9 implantable device, the transdermal needle, and the external generator. MRI-compatible and designed for repeated use during chemotherapy cycles to enable enhanced drug delivery to the brain.

Quantifiable outcome

  • 4-6x increase in drug concentrations in brain tissue after SonoCloud-9 mediated BBB opening
  • +3 more outcomes

Companies that use CarThera

Customer profile

Named customers3 records

Segments4 records

Ideal customer profiles2 records

CarThera technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

CarThera partnerships and signals

Strategic signal

Partnerships

Eight partnerships are on record, tiered core and minor.

  • AgenuscoreStrategic or Co-development Partner · 9 April 2024Partnership with Agenus and Northwestern University for Phase 2a trial combining SonoCloud-9® with checkpoint inhibitors (anti-CTLA-4, anti-PD-1) to treat newly diagnosed glioblastoma. World-first trial that could change standard of care for unmethylated glioblastoma patients.
  • Accord HealthcarecoreStrategic or Co-development Partner · 6 November 2023Strategic collaboration with Accord Healthcare Limited, a leading pharmaceutical company, for the supply of carboplatin. This partnership ensures reliable drug supply for clinical trials and potential commercialization of the SonoCloud®-carboplatin combination therapy.
  • LantheuscoreStrategic or Co-development Partner · 9 December 2019Strategic collaboration with US-based Lantheus to provide microbubbles for use with the SonoCloud device. Microbubbles are an essential component of the LIPU technology as they oscillate when exposed to ultrasound to trigger BBB opening.
  • KIYATECminorStrategic or Co-development Partner · 18 November 2019Clinical collaboration with KIYATEC to advance innovation and improve treatments for patients with glioblastoma, potentially incorporating personalized medicine approaches.
  • Northwestern UniversitycoreStrategic or Co-development PartnerLong-standing research and clinical collaboration with Northwestern University in Chicago for development of SonoCloud technology. Multiple joint clinical trials including SC9-ABX (Phase 1/2 with nab-paclitaxel) and SC9-IMMUNO (Phase 2a with checkpoint inhibitors). Dr. Amy Heimberger and Dr. Adam Sonabend from Northwestern are key collaborators.
  • AP-HP (Assistance Publique Hôpitaux de Paris)coreStrategic or Co-development PartnerSpin-off from AP-HP, the largest hospital group in Europe. Ongoing institutional collaboration for multiple clinical trials including SONOFIRST, SONOKID, and BOREAL. Professor Alexandre Carpentier, founder and inventor, is chief of neurosurgery at Pitié-Salpêtrière University Hospital (AP-HP).
  • INSERMminorStrategic or Co-development PartnerResearch collaboration with INSERM (French National Institute of Health and Medical Research) for pre-clinical and translational research on therapeutic ultrasound.
  • UCSFminorStrategic or Co-development PartnerCollaboration with University of California San Francisco for clinical research and development of SonoCloud technology. Dr. Mitchel Berger, Director of the Brain Tumor Center at UCSF, serves on Carthera's Scientific Advisory Board.

Scale indicators6 records

Recent moves7 records

Expansion highlights6 records

CarThera competitors and assessment

Company assessment

Direct peers

  • InSightec: InSightec develops transcranial MR-guided focused ultrasound systems for non-invasive blood-brain barrier opening and other neurological applications. It is a direct peer in the ultrasound-mediated BBB opening category, though its approach is non-invasive rather than implantable.
  • NovoCure: NovoCure markets Tumor Treating Fields (TTFields) therapy for newly diagnosed and recurrent glioblastoma. It is a direct commercial peer serving the same primary indication with a novel device-based mechanism, representing the standard-of-care alternative SonoCloud would need to displace or complement.
  • Diffusion Pharmaceuticals (Aadi Bioscience): Aadi Bioscience focuses on treating rare cancers including glioblastoma with nanoparticle albumin-bound therapeutics. It is a direct peer serving the same recurrent glioblastoma indication with a complementary drug-delivery approach seeking to overcome the BBB.

Emerging players

  • NaviFUS: NaviFUS is a Taiwan-based clinical-stage company developing non-invasive focused ultrasound for blood-brain barrier opening in glioblastoma and other CNS indications. It is an emerging peer pursuing a similar therapeutic mechanism through a different delivery modality.
  • Theraclion: Theraclion is a French clinical-stage company developing high-intensity focused ultrasound (HIFU) for benign thyroid and breast tumors. It is an emerging peer in the European therapeutic ultrasound space with comparable modality but non-overlapping indications.
  • Cordance Medical: Cordance Medical is an emerging company developing non-invasive focused ultrasound for transient BBB opening to enable drug delivery. It targets the same core mechanism as SonoCloud without the implant, making it a thematic emerging peer in the BBB-opening space.
  • Medicenna Therapeutics: Medicenna Therapeutics develops IL-2 and IL-4 Superkines for recurrent glioblastoma and other solid tumors. It is an emerging peer competing in the same recurrent GBM indication with a novel immunotherapeutic approach, often cited as a comparable clinical-stage oncology biotech.

Broad incumbents

  • EDAP TMS: EDAP TMS is a publicly listed therapeutic ultrasound company commercializing high-intensity focused ultrasound (HIFU) for prostate cancer and other urological indications. It is a broad incumbent in therapeutic ultrasound, and CarThera's CEO previously led the launch of EDAP's Ablatherm device.
  • Profound Medical: Profound Medical develops MR-guided transurethral ultrasound ablation systems primarily for prostate disease. It is a broad incumbent in the therapeutic ultrasound category using overlapping core technology (focused ultrasound ablation) for adjacent clinical applications.
  • SonaCare Medical (Sonablate): Sonablate (SonaCare Medical) commercializes high-intensity focused ultrasound ablation systems for prostate tissue. It is a broad incumbent in the HIFU device category, with overlapping ultrasound ablation technology but a different clinical focus.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

CarThera social profiles

Digital presence

CarThera compliance and trust

Trust signal

Compliance1 record

CarThera financial estimates

Financial estimate

Revenue estimate

Valuation estimate

CarThera leadership team

Management profile

Number of profiles

Profiles6 records

CarThera subsidiaries and ownership

Company hierarchy

Subsidiaries1 record

CarThera funding detail

Funding detail

Funding overview

Funding rounds8 records

Investors10 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

CarThera M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about CarThera

What does CarThera do?

CarThera develops the SonoCloud® platform, an implantable ultrasound-based medical device system that emits low-intensity pulsed ultrasound (LIPU) to temporarily and reversibly open the blood-brain barrier (BBB). The system consists of an intracranial implant (SonoCloud-1 or SonoCloud-9), an external generator, and a transdermal needle for activation. Four minutes of ultrasound opens the BBB for several hours, enabling 4-6x increased concentration of therapeutic molecules in the brain for treatment of glioblastoma, brain metastases, and neurodegenerative diseases.

Is CarThera a public or private company?

CarThera is a private company. It is classified as venture growth investor backed and is currently operating.

When was CarThera founded?

CarThera was founded in 2010. It employs 11 to 50 people.

Where is CarThera based?

CarThera is headquartered in Lyon, France, in the Europe region.

How does CarThera make money?

One revenue line is on record: medical Device Sales.

Who are CarThera's main competitors?

Direct peers on record are InSightec, NovoCure and Diffusion Pharmaceuticals (Aadi Bioscience). Emerging players are NaviFUS, Theraclion, Cordance Medical and Medicenna Therapeutics. Broad incumbents are EDAP TMS, Profound Medical and SonaCare Medical (Sonablate).

Does CarThera have an API?

No public API is recorded for CarThera.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
The Cancer LetterFDA, EMA grant Orphan Drug Designation to Carthera for carboplatin with SonoCloud technology in gliomaThe FDA and the European Medicines Agency granted Orphan Drug Designation to Carthera for its carboplatin treatment using SonoCloud technology in malignant glioma. This designation is a regulatory step that provides incentives for developing drugs for rare diseases. The decision facilitates further clinical development and potential market entry for this specific therapy.Tech.euCarthera secures additional €4.5M for innovative medtech to treat brain disordersMedtech company Carthera secured an additional €4.5 million in funding, bringing its total Series B financing to €42 million. This capital will support the launch of a pivotal clinical trial for SonoCloud®, an implant designed to treat recurrent glioblastoma by temporarily opening the blood-brain barrier. The investment round included new participation from US-based Unorthodox Ventures alongside existing shareholders.AlaCarthera brings Series B round to €42M with additional €4.5M fundingCarthera has secured a total of €42M in Series B funding, including an additional €4.5M from new investor Unorthodox Ventures, to launch its first registrational clinical trial for recurrent glioblastoma using its SonoCloud device. The company will also utilize the capital to expand its pipeline in neurodegenerative diseases and pursue collaborations with pharmaceutical partners. This financing strengthens Carthera's investor pool with its first US-based venture capital firm while supporting ongoing clinical development in Europe and the United States.FinSMEsCarthera Raises Additional €4.5M; Brings Series B round to €42MParis-based medtech company Carthera raised an additional €4.5M, bringing its Series B funding round to a total of €42M with participation from investors including Unorthodox Ventures and Supernova Invest. The capital will support the launch of a pivotal registrational trial for SonoCloud, an implant designed to open the blood-brain barrier for treating recurrent glioblastoma. Additionally, funds will be used to expand the company's pipeline in neurodegenerative diseases and establish collaborations with pharmaceutical partners.Lespepitestech122.333 Millions D'euros Levés Par Les Startups Françaises - Semaine 26 - 2023French startups raised a total of 122.333 million euros across 18 funding operations during week 26 of 2023, according to data compiled by Eldorado.co. The largest investments went to Carthera and Gleamer, both securing Series B rounds for their medical technology and AI radiology solutions respectively. This aggregate report highlights activity across diverse sectors including biotech, cybersecurity, and sustainable energy within the French ecosystem.AlaCarthera closes €37.5M Series B funding roundCarthera announced the closing of its €37.5 million Series B funding round, led by an undisclosed investor alongside the European Innovation Council Fund and existing backers. The company will utilize these funds to launch a pivotal multicenter trial for its SonoCloud ultrasound device in treating recurrent glioblastoma and to advance its broader clinical pipeline.Les EchosCarthera boucle une série B de 37,5 M€Carthera, a medtech spin-off of AP-HP and Sorbonne University, has closed a €37.5 million Series B funding round led by an undisclosed investor. This capital raise follows a previous €9 million Series A in 2018 and is intended to support the company's progression into phase 3 clinical trials for its ultrasonic brain disease treatment device.FinSMEsCarthera Closes €37.5M Series B FundingCarthera, a Lyon and Paris-based medtech company, has closed a €37.5 million Series B funding round led by an undisclosed investor alongside several existing backers including the European Innovation Council Fund. The company intends to utilize these funds to launch a pivotal multicenter trial for its SonoCloud technology and continue developing its clinical pipeline for brain disorders.Mpo-magCarThera Appoints Board ChairmanCarThera appointed Pascal E. R. Girin as board chairman, bringing experience from roles including CEO of Balt. The company is recruiting patients for a clinical trial with its SonoCloud-9 implantable ultrasound device, which covers a volume nine times larger than the previous generation. The device aims to treat glioblastoma and other brain conditions.